This is the authors' abstract. We don't add key points for this paper.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) (previously referred as blastic natural killer cell leukemia/lymphoma or agranular CD4+/CD56+ hematodermic neoplasm) is a rare hematologic malignancy derived from the precursors of plasmacytoid dendritic cells and is now classified as a rare subtype of acute myeloid leukemia according to the 2008 WHO classification. 1 The disease is a clinically aggressive tumor with a high frequency of cutaneous and bone marrow (BM) involvement. Tumor cells express CD4, CD43, CD45RA and CD56, as well as the plasmacytoid dentritic cell-associated antigens CD123, BDCA-2/CD303, TCL1 and CTLA1.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Nakamura et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: